Literature DB >> 31734909

Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology.

Pierre R Bourque1,2, J Brooks3,4, J Warman-Chardon3,4, A Breiner3,4.   

Abstract

The discriminative value of CSF total protein (CSF-TP) in subtypes of Guillain-Barré syndrome has not been well documented in North-American patients. We reviewed 173 cases from a single institution, comprising the following clinical categories of neuropathy: 134 Sensorimotor (SM) GBS, 13 Motor (M) GBS, 8 Localized (L) GBS, and 18 Miller Fisher syndrome (MFS). We grouped the electrophysiological interpretation in primarily demyelinating, primarily axonal and normal / equivocal categories. Mean CSF-TP were substantially higher for SM and L-GBS, as well as cases classified as Acute-onset chronic inflammatory demyelinating polyneuropathy. They were lower for M-GBS and L-GBS. The most statistically significant correlation was found for elevated CSF-TP in GBS cases showing an electrophysiologic pattern classified as demyelinating (1.56 g/L) compared with axonal (0.68 g/L) or normal/ equivocal patterns (0.65 g/L). There was a correlation between CSF-TP and time interval between symptom onset and lumbar puncture. There was a weak correlation between CSF-TP and maximal overall-clinical severity grade, which was likely mostly determined by the electorphysiological pattern. Though CSF-TP is a sensitive test for GBS in the second week after onset, it may not be a reliable predictor of clinical severity. There is a robust association of CSF-TP elevation and a demyelinative electrophysiologic pattern and a suggestion that lower mean CSF-TP values can be expected in GBS-spectrum disorders thought to represent nodo-paranodopathies.

Entities:  

Keywords:  Albuminocytologic dissociation; Cerebrospinal fluid protein; Guillain–Barre syndrome; Immune neuropathy

Mesh:

Year:  2019        PMID: 31734909     DOI: 10.1007/s00415-019-09634-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

Review 1.  The Miller Fisher syndrome. Review of the literature.

Authors:  P Berlit; J Rakicky
Journal:  J Clin Neuroophthalmol       Date:  1992-03

2.  Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes.

Authors:  Anna Hiu Yi Wong; Thirugnanam Umapathi; Yukihiro Nishimoto; Yu Zhong Wang; Yee Cheun Chan; Nobuhiro Yuki
Journal:  J Peripher Nerv Syst       Date:  2015-03       Impact factor: 3.494

3.  Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.

Authors:  Liselotte Ruts; Rinske van Koningsveld; Pieter A van Doorn
Journal:  Neurology       Date:  2005-07-12       Impact factor: 9.910

4.  Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice?

Authors:  Yusuf A Rajabally; Marie-Christine Durand; James Mitchell; David Orlikowski; Guillaume Nicolas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-05-09       Impact factor: 10.154

5.  Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination.

Authors:  Y Nishimoto; M Odaka; K Hirata; N Yuki
Journal:  J Neuroimmunol       Date:  2004-03       Impact factor: 3.478

6.  Controlled trial prednisolone in acute polyneuropathy.

Authors:  R A Hughes; J M Newsom-Davis; G D Perkin; J M Pierce
Journal:  Lancet       Date:  1978-10-07       Impact factor: 79.321

7.  Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients.

Authors:  Lucas Alessandro; José M Pastor Rueda; Miguel Wilken; Luis Querol; Mariano Marrodán; Julián N Acosta; Alberto Rivero; Fabio Barroso; Mauricio F Farez
Journal:  J Peripher Nerv Syst       Date:  2018-06-25       Impact factor: 3.494

8.  Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria.

Authors:  Christiaan Fokke; Bianca van den Berg; Judith Drenthen; Christa Walgaard; Pieter Antoon van Doorn; Bart Casper Jacobs
Journal:  Brain       Date:  2013-10-26       Impact factor: 13.501

9.  Cerebrospinal Fluid Total Protein Reference Intervals Derived from 20 Years of Patient Data.

Authors:  Christopher R McCudden; John Brooks; Priya Figurado; Pierre R Bourque
Journal:  Clin Chem       Date:  2017-10-11       Impact factor: 8.327

10.  Age matters: Impact of data-driven CSF protein upper reference limits in Guillain-Barré syndrome.

Authors:  Pierre R Bourque; John Brooks; Christopher R McCudden; Jodi Warman-Chardon; Ari Breiner
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-05-21
View more
  1 in total

1.  Cerebrospinal fluid analysis in Guillain-Barré syndrome: value of albumin quotients.

Authors:  Jakob Rath; Gudrun Zulehner; Bernadette Schober; Anna Grisold; Martin Krenn; Hakan Cetin; Fritz Zimprich
Journal:  J Neurol       Date:  2021-03-02       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.